Full Text Journal Articles by
Author Shi Ming Tu

Advertisement

Find full text journal articles






Diagnostic performance of 18F-fluciclovine PET/CT in prostate cancer patients with rising PSA level ≤ 0.5 ng/ml after multiple treatment failures.

Ajalaya Teyateeti, Achiraya Teyateeti, Gregory C Ravizzini, Guofan Xu, Chad Tang, Shi-Ming Tu, Homer A Macapinlac, Yang Lu,

This retrospective study is to assess the performance of <sup>18</sup>F-Fluciclovine PET/CT in prostate cancer (PC) patients with multiple treatment failures and prostate-specific antigen (PSA) ≤ 0.5 ng/mL. PC patients with multiple treatment failures who had PSA level within 2-week interval of <sup>18</sup>F-Fluciclovine PET/CT (PSA<sub>PET</sub>) ≤ 0.5 ng/mL were identified in ... Read more >>

Am J Nucl Med Mol Imaging (American journal of nuclear medicine and molecular imaging)
[2021, 11(2):87-98]

Cited: 0 times

View full text PDF listing >>



Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.

Nicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, John Davis, Amado Zurita, Xuemei Wang, Shi-Ming Tu, Brian F Chapin, Ana Aparicio, Paul Corn, Jennifer Wang, Sumit K Subudhi, John Araujo, John Papadopoulos, Lisa Pruitt, Justin A Weldon, Christopher J Logothetis, Eleni Efstathiou,

<h4>Background</h4>Intermittent androgen deprivation therapy (ADT) in biochemically recurrent castration-naïve prostate cancer is non-inferior to continuous therapy. We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to ADT will further reduce the duration of treatment exposure by prolonging time to prostate-specific antigen (PSA) recurrence without impacting eugonad state recovery.<h4>Methods</h4>This ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 157:259-267]

Cited: 0 times

View full text PDF listing >>



Advertisement

Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity.

Shi-Ming Tu, Miao Zhang, Christopher G Wood, Louis L Pisters,

In many respects, heterogeneity is one of the most striking revelations and common manifestations of a stem cell origin of cancer. We observe heterogeneity in myriad mixed tumors including testicular, lung, and breast cancers. We recognize heterogeneity in diverse tumor subtypes in prostate and kidney cancers. From this perspective, we ... Read more >>

Cancers (Basel) (Cancers)
[2021, 13(16):]

Cited: 0 times

View full text PDF listing >>



Somatic-type Malignancies in Testicular Germ Cell Tumors: A Clinicopathologic Study of 63 Cases.

Michael J Hwang, Ameer Hamza, Miao Zhang, Shi-Ming Tu, Louis L Pisters, Bogdan Czerniak, Charles C Guo,

The development of somatic-type malignancies (SMs) in testicular germ cell tumors (GCTs) is a rare but well-recognized phenomenon. We studied the pathologic features of 63 GCTs with SMs in the testis (n=22) or metastases (n=41) and correlated these features with clinical outcomes. The patients with SMs in the testis (median ... Read more >>

Am J Surg Pathol (The American journal of surgical pathology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Testicular germ cell tumors type 2 have high RNA expression of LDHB, the gene for lactate dehydrogenase subunit B.

Finn Edler von Eyben, Jorge Parraga-Alava, Shi-Ming Tu,

This study analyzed RNA expression of genes for three serum tumor markers, alpha fetoprotein (AFP), human chorionic gonadotropin (hCG), and lactate dehydrogenase (LDH), in patients with testicular germ cell tumors (TGCT) type 2. The gene AFP encodes AFP, the gene for chorionic gonadotropin beta polypeptide 5 (CGB5) encodes a major ... Read more >>

Asian J Androl (Asian journal of andrology)
[2021, 23(4):357-362]

Cited: 0 times

View full text PDF listing >>



Optimizing the diagnosis and management of ductal prostate cancer.

Weranja Ranasinghe, Daniel D Shapiro, Miao Zhang, Tharakeswara Bathala, Nora Navone, Timothy C Thompson, Bradley Broom, Ana Aparicio, Shi-Ming Tu, Chad Tang, John W Davis, Louis Pisters, Brian F Chapin,

Ductal adenocarcinoma (DAC) is the most common variant histological subtype of prostate carcinoma and has an aggressive clinical course. DAC is usually characterized and treated as high-risk prostatic acinar adenocarcinoma (PAC). However, DAC has a different biology to that of acinar disease, which often poses a challenge for both diagnosis ... Read more >>

Nat Rev Urol (Nature reviews. Urology)
[2021, 18(6):337-358]

Cited: 0 times

View full text PDF listing >>



Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.

Andrew W Hahn, Jad Chahoud, Matthew T Campbell, Daniel D Karp, Jennifer Wang, Bettzy Stephen, Shi-Ming Tu, Curtis A Pettaway, Aung Naing,

<h4>Background</h4>Treatment options for unresectable, locally advanced or metastatic penile squamous cell carcinoma (SCC) are limited. Previous studies have shown that 40-62% of patients with penile SCC express PD-L1. We report three cases of locally advanced or metastatic penile SCC treated with pembrolizumab.<h4>Case presentations</h4>Herein, we present three patients with recurrent, locally ... Read more >>

Invest New Drugs (Investigational new drugs)
[2021, 39(5):1405-1410]

Cited: 1 time

View full text PDF listing >>



Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study.

Apostolia Maria Tsimberidou, David S Hong, Siqing Fu, Daniel D Karp, Sarina Piha-Paul, Merrill S Kies, Vinod Ravi, Vivek Subbiah, Sunil M Patel, Shi-Ming Tu, Filip Janku, John Heymach, Amber Johnson, Carrie Cartwright, Li Zhao, Jianhua Zhang, Donald A Berry, David J Vining, Andrew Futreal, Vincent A Miller, Funda Meric-Bernstam,

Precision medicine is associated with favorable outcomes in selected patients with cancer. Herein, we report an interim analysis of IMPACT2, an ongoing randomized study evaluating genomic profiling and targeted agents in metastatic cancer. Patients with metastatic cancer underwent tumor genomic profiling (ClinialTrials.gov: NCT02152254), and 69 patients met the criteria for ... Read more >>

NPJ Precis Oncol (NPJ precision oncology)
[2021, 5(1):21]

Cited: 1 time

View full text PDF listing >>



Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.

Apostolia-Maria Tsimberidou, Henry Hiep Vo, Vivek Subbiah, Filip Janku, Sarina Piha-Paul, Bulent Yilmaz, Jing Gong, Mohammad Faraz Naqvi, Shi-Ming Tu, Matthew Campbell, Funda Meric-Bernstam, Aung Naing,

<h4>Lessons learned</h4>Advanced germ cell tumors are aggressive and associated with poor prognosis. Pembrolizumab was overall well tolerated in 12 heavily pretreated patients. Three patients had radiographic stable disease that lasted for 10.9 months, 5.5 months, and 4.5 months, respectively. Published data of immunotherapeutic agents in patients with advanced germ cell ... Read more >>

Oncologist (The oncologist)
[2021, 26(7):558-e1098]

Cited: 0 times

View full text PDF listing >>



The Cancer Genome: Paradigm or Paradox?

Shi-Ming Tu,

Nowadays, many professionals are sequencing the DNA and studying the cancer genome. However, if the genetic theory of cancer is flawed, our faith in the cancer genome will falter. If gene sequencing is only a tool, we should question what we are making or creating with this tool. When we ... Read more >>

Cancers (Basel) (Cancers)
[2021, 13(4):]

Cited: 0 times

View full text PDF listing >>



Curing Cancer: Lessons from a Prototype.

Shi-Ming Tu, Louis L Pisters,

Germ cell tumor of the testis (TGCT) is a remarkably curable solid tumor even when it is widely metastatic and patently heterogeneous. It provides invaluable clues about the origin and nature of metastasis and heterogeneity, cancer dormancy and late recurrence, drug sensitivity and resistance, tumor immunity, and spontaneous remission that ... Read more >>

Cancers (Basel) (Cancers)
[2021, 13(4):]

Cited: 0 times

View full text PDF listing >>



Application of a Successful Germ Cell Tumor Paradigm to the Challenges of Common Adult Solid Cancers.

Shi-Ming Tu, Matthew Campbell, Amishi Shah, Christopher J Logothetis,

When we aspire to cure cancer, we may need to search no further than a curable cancer, such as Germ Cell Tumor of the Testis (TGCT). After all, a germ cell is a primordial stem cell. Importantly, TGCT provides a classic stem cell model of cancer that teaches us some ... Read more >>

J Cell Sci Ther (Journal of cell science & therapy)
[2021, 12(6):]

Cited: 1 time

View full text PDF listing >>



Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.

Weranja Ranasinghe, Daniel D Shapiro, Hyunsoo Hwang, Xuemei Wang, Chad A Reichard, Mohamed Elsheshtawi, Mary F Achim, Tharakeswara Bathala, Chad Tang, Ana Aparicio, Shi-Ming Tu, Nora Navone, Timothy C Thompson, Louis Pisters, Patricia Troncoso, John W Davis, Brian F Chapin,

<h4>Background</h4>Ductal prostate adenocarcinoma (DAC) is a rare, aggressive, histologic variant of prostate cancer that is treated with conventional therapies, similar to high-risk prostate adenocarcinoma (PAC).<h4>Objective</h4>To assess the outcomes of men undergoing definitive therapy for DAC or high-risk PAC and to explore the effects of androgen deprivation therapy (ADT) in improving ... Read more >>

Eur Urol (European urology)
[2021, 79(2):298-306]

Cited: 1 time

View full text PDF listing >>



Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor.

Eric C Umbreit, Bilal A Siddiqui, Michael J Hwang, Aron Y Joon, Tapati Maity, Mary E Westerman, Kelly W Merriman, Hussam Alhasson, Joma Uthup, Tao Guo, Joseph A Moore, John F Ward, Jose A Karam, Christopher G Wood, Louis L Pisters, Miao Zhang, Shi-Ming Tu,

Although genetic changes may be pivotal in the origin of cancer, cellular context is paramount. This is particularly relevant in a progenitor germ cell tumor and its differentiated mature teratoma counterpart when it concerns tumor heterogeneity and cancer dormancy in subsequent second malignancies (subsequent malignant neoplasms (SMNs)). From our tumor ... Read more >>

Cancers (Basel) (Cancers)
[2020, 12(12):]

Cited: 3 times

View full text PDF listing >>



Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications.

Eric C Umbreit, Andrew G McIntosh, Chalairat Suk-Ouichai, Luis A Segarra, Levi C Holland, Bryan M Fellman, Stephen B Williams, Arun Z Thomas, Shi-Ming Tu, Curtis A Pettaway, Louis L Pisters, John F Ward, Christopher G Wood, Jose A Karam,

<h4>Background</h4>Postchemotherapy retroperitoneal lymphadenectomy (PC-RPLND) is an essential, yet potentially morbid, therapy for the management of patients with advanced germ cell tumors. In the current study, the authors sought to define the complication profile of PC-RPLND using validated grading systems for intraoperative adverse events (iAEs) and early postoperative complications.<h4>Methods</h4>Between 2000 and ... Read more >>

Cancer (Cancer)
[2020, 126(22):4878-4885]

Cited: 1 time

View full text PDF listing >>



A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.

Nicholas Spetsieris, Myrto Boukovala, Justin A Weldon, Alexandros Tsikkinis, Anh Hoang, Ana Aparicio, Shi-Ming Tu, John C Araujo, Amado J Zurita, Paul G Corn, Lance Pagliaro, Jeri Kim, Jennifer Wang, Sumit K Subudhi, Nizar M Tannir, Christopher J Logothetis, Patricia Troncoso, Xuemei Wang, Sijin Wen, Eleni Efstathiou,

<h4>Background</h4>Resistance to novel androgen signaling inhibition and metastatic castration-resistant prostate cancer (mCRPC) progression is likely dependent on tumor microenvironment interactions. The Src pathway and neoangiogenesis have been implicated in prostate cancer progression. We studied the effect of adding the targeted agents dasatinib and sunitinib to abiraterone acetate (AA) in men ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2021, 19(1):22-31.e5]

Cited: 1 time

View full text PDF listing >>



Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.

Bo Chen, Tharakeswara K Bathala, Guofang Xu, Ajalaya Teyateeti, Brian F Chapin, Chad Tang, Shi-Ming Tu, Homer A Macapinlac, Yang Lu,

<h4>Purpose</h4>The aim of this study was to investigate the imaging diagnostic performance of F-fluciclovine PET/CT and pelvic multiparametric MRI (mpMRI) for prostate cancer in the setting of rising PSA after initial treatment, with a focus on detection of recurrent and metastatic prostate cancer in the pelvis.<h4>Methods</h4>Patients with prostate cancer who ... Read more >>

Clin Nucl Med (Clinical nuclear medicine)
[2020, 45(5):349-355]

Cited: 0 times

View full text PDF listing >>



Patterns of metastases of prostatic ductal adenocarcinoma.

Weranja K B Ranasinghe, Nathan A Brooks, Mohamed A Elsheshtawi, John W Davis, Tharakeswara K Bathala, Chad Tang, Patricia Troncoso, Ana Aparicio, Shi-Ming Tu, Louis L Pisters, Brian F Chapin,

<h4>Background</h4>The current study was conducted to investigate the patterns of metastases in men with metastatic prostatic ductal adenocarcinoma (DAC) and recurrence patterns after therapy.<h4>Methods</h4>All patients with a new diagnosis of DAC with de novo metastases and those with localized disease who developed metastases after treatment and were treated at the ... Read more >>

Cancer (Cancer)
[2020, 126(16):3667-3673]

Cited: 2 times

View full text PDF listing >>



Editorial Comment.

Andrew G McIntosh, Shi-Ming Tu,

J Urol (The Journal of urology)
[2020, 203(6):1154]

Cited: 0 times

View full text PDF listing >>



Phase 2 study of pembrolizumab in patients with advanced rare cancers.

Aung Naing, Funda Meric-Bernstam, Bettzy Stephen, Daniel D Karp, Joud Hajjar, Jordi Rodon Ahnert, Sarina A Piha-Paul, Rivka R Colen, Camilo Jimenez, Kanwal P Raghav, Renata Ferrarotto, Shi-Ming Tu, Matthew Campbell, Linghua Wang, Sarjeel H Sabir, Coya Tapia, Chantale Bernatchez, Michael Frumovitz, Nizar Tannir, Vinod Ravi, Saria Khan, Jeane M Painter, Abulrahman Abonofal, Jing Gong, Anas Alshawa, Lacey M McQuinn, Mingxuan Xu, Sara Ahmed, Vivek Subbiah, David S Hong, Shubham Pant, Timothy A Yap, Apostolia M Tsimberidou, Ecaterina E Ileana Dumbrava, Filip Janku, Siqing Fu, Richard M Simon, Kenneth R Hess, Gauri R Varadhachary, Mouhammed Amir Habra,

<h4>Background</h4>Patients with advanced rare cancers have poor prognosis and few treatment options. As immunotherapy is effective across multiple cancer types, we aimed to assess pembrolizumab (programmed cell death 1 (PD-1) inhibitor) in patients with advanced rare cancers.<h4>Methods</h4>In this open-label, phase 2 trial, patients with advanced rare cancers whose tumors had ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2020, 8(1):]

Cited: 21 times

View full text PDF listing >>



Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment.

Bilal A Siddiqui, Miao Zhang, Louis L Pisters, Shi-Ming Tu,

Testicular germ cell tumors are the most common solid tumors in young men. These cancers represent a success story of modern medicine in our ability to cure young patients and offer decades of life, with a 5-year survival rate of approximately 95%. This review outlines the staging and risk classification ... Read more >>

Transl Androl Urol (Translational andrology and urology)
[2020, 9(Suppl 1):S56-S65]

Cited: 2 times

View full text PDF listing >>



A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer.

Paul G Corn, Miao Zhang, Graciela M Nogueras-Gonzalez, Lianchun Xiao, Amado J Zurita, Sumit K Subudhi, Shi-Ming Tu, Ana M Aparicio, Cristian Coarfa, Kimal Rajapakshe, Shixia Huang, Nora M Navone, Sue-Hwa Lin, Guocan Wang, Sumankalai Ramachandran, Mark A Titus, Theocharis Panaretakis, Gary E Gallick, Eleni Efstathiou, Patricia Troncoso, Christopher Logothetis,

<h4>Purpose</h4>Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy (ADT) in hormone-naïve metastatic prostate cancer (HNMPCa).<h4>Patients and methods</h4>Patients received ADT plus cabozantinib starting at 60 mg daily. The primary endpoint was ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, 26(5):990-999]

Cited: 0 times

View full text PDF listing >>



A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer.

Myrto Boukovala, Nicholas Spetsieris, Justin A Weldon, Alexandros Tsikkinis, Anh Hoang, Ana Aparicio, Shi-Ming Tu, John C Araujo, Amado J Zurita, Paul G Corn, Lance Pagliaro, Jeri Kim, Jennifer Wang, Sumit K Subudhi, Nizar M Tannir, Christopher J Logothetis, Patricia Troncoso, Sijin Wen, Eleni Efstathiou,

<h4>Background</h4>The unmet need for predictive biomarkers emerged from the unpredictable pattern of response to androgen signalling inhibition in metastatic castration-resistant prostate cancer (mCRPC). Here, we report on the testing of a previously identified candidate androgen signalling signature associated with response to androgen signalling inhibition.<h4>Patients and methods</h4>We report on the outcome ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2020, 127:67-75]

Cited: 3 times

View full text PDF listing >>



Rapidly enlarging abdominal mass in a patient with recurrent germ cell tumor.

Lauren Ho, Louis Pisters, Shi-Ming Tu,

This clinical image illustrates the alarming growth rate for an embryonal carcinoma, as well as its highly curable nature. For similar cases, early diagnosis and treatment are key. ... Read more >>

Clin Case Rep (Clinical case reports)
[2019, 7(11):2285-2286]

Cited: 0 times

View full text PDF listing >>



Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.

Paul G Corn, Elisabeth I Heath, Amado Zurita, Naveen Ramesh, Lianchun Xiao, Emi Sei, Elsa Li-Ning-Tapia, Shi-Ming Tu, Sumit K Subudhi, Jennifer Wang, Xuemei Wang, Eleni Efstathiou, Timothy C Thompson, Patricia Troncoso, Nicholas Navin, Christopher J Logothetis, Ana M Aparicio,

<h4>Background</h4>Taxane-platinum combinations have shown promising activity in metastatic castration-resistant prostate cancers in single-group clinical studies but not in randomised trials. Distinct biological subsets of the disease might derive the greatest benefit from the addition of platinum. We aimed to determine whether adding carboplatin to cabazitaxel would improve the outcomes of ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2019, 20(10):1432-1443]

Cited: 20 times

View full text PDF listing >>



Advertisement


Disclaimer

1.0217 s